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Abstract

Neonatal abstinence syndrome (NAS) is a postnatal withdrawal syndrome among neonates
born to drug-dependent mothers. NAS poses a significant health and fiscal challenge
nationally, with its incidence increasing by a factor of six (1.20 to 6.7 per 1,000 hospital
births/year) along with the concomitant rise in health care cost from 2000-2016. Besides
national data, it is critical to quantify NAS at the state-level to identify the target areas for
prevention. Given the higher opioid prescribing rates among pregnant women in Nevada, it is
critical to assess the health and financial magnitude of NAS in the state. The objectives of
this cross-sectional study were to describe the burden of NAS in Nevada from 2016 to 2018,
including incidence, hospital utilization trends and cost, and differences across demographic
and clinical characteristics between newborns with and without a NAS diagnosis. This study
utilized hospital administrative data from the Center for Health Information Analysis. The
units of observation were in-patient pediatric discharges with a diagnostic code of NAS
following maternal drug abuse. Statistical analyses included estimation of crude incidence
rates per 1,000 hospital births, bootstrapped significance testing for independent-samples ttests and chi-square tests, and multilevel logistic regression modelling. Results demonstrated
an increase in overall NAS incidence of 8 per 1,000 hospital births, with disproportionate
effects in certain demographic groups. The incidence of NAS was the highest among white
newborns (12 per 1,000 hospital births) and those who were Medicaid insured (13.2 per 1,000
hospital births). NAS infants were more likely to experience other clinical conditions, longer
hospital stays (mean length of stay 17 days), incur higher health care costs, and undergo
intense medical procedures. NAS has taken a heavy toll on Nevada’s health care system with
over 75% of the total cost attributed to state Medicaid programs. These findings support the
need for targeted interventions in clinical and public health settings aimed at prevention and
burden reduction of NAS in Nevada.
iii

Acknowledgements
First and foremost, praises and thanks to the God, the Almighty, for His showers of blessings
throughout my research work to complete the research successfully.
I would like to acknowledge everyone who played a role in my academic accomplishments.
I would like to express my sincere gratitude to my advisor and chair Dr. Patricia Cruz for her
continued support, patience, motivation, and enthusiasm throughout my studies and research.
I could not have imagined having a better advisor and mentor for my Ph.D. study. Thanks for
standing by me in every situation.
I would like to thank my committee members, Dr. Mark Buttner, Dr. Neeraj Bhandari, Dr.
Chad Cross, Dr. Jennifer Pharr, Dr. Farooq Abdulla & Dr. Anne Weisman, each of whom has
provided patient advice and guidance throughout the research process. Their thoughtful
questions and comments were valued greatly. Thank you for your unwavering support.
I am extremely grateful to my family for the love and prayers. I am very much thankful to my
husband and my daughter for their love, understanding, prayers, and continuing support to
complete this research work. Without you, I could never have reached this current level of
success.
This study is dedicated to my father, who is watching me from the heaven and showered
blessings at each venture of my life.

iv

Table of Contents
Abstract ........................................................................................................................... iii
Acknowledgements .......................................................................................................... iv
List of Tables ................................................................................................................. viii
List of Figures .................................................................................................................. ix
Chapter 1. Introduction ................................................................................................... 1
Background .................................................................................................................... 1
Description of the problem ............................................................................................. 3
Purpose of the study ....................................................................................................... 6
Significance of the study ................................................................................................ 6
Chapter 2. Literature review ........................................................................................... 7
NAS as a health and fiscal challenge .............................................................................. 7
NAS as a peril of maternal drug use................................................................................ 8
Efforts to reverse the opioid epidemic and legislative updates ......................................... 9
Chapter 3. Methods ........................................................................................................ 12
Research questions ....................................................................................................... 12
Specific aims ................................................................................................................ 13
Study design and setting ............................................................................................... 14
Neonatal Abstinence Syndrome Standardized Case Definition...................................... 15
Data source................................................................................................................... 15
Data acquisition ............................................................................................................ 16

vii

Data storage and protection .......................................................................................... 16
Inclusion and Exclusion Criteria ................................................................................... 17
Measures ...................................................................................................................... 17
Outcomes ..................................................................................................................... 18
Statistical Analysis ....................................................................................................... 20
Chapter 4. Results .......................................................................................................... 24
Incidence ...................................................................................................................... 24
Demographic and Clinical characteristics ..................................................................... 31
Health care utilization patterns ..................................................................................... 33
Health care cost ............................................................................................................ 36
Predictors ..................................................................................................................... 38
Results interpretation and hypotheses testing ................................................................ 41
Chapter 5. Discussion ..................................................................................................... 45
Limitations ................................................................................................................... 48
Strengths ...................................................................................................................... 50
Implications for public health practice .......................................................................... 50
Future work .................................................................................................................. 51
Appendices...................................................................................................................... 52
Appendix A. NAS Assessment Tools .......................................................................... 52
Appendix A.1. Modified Finnegan Scoring System ...................................................... 52
Appendix A.2. Eat, Sleep, Console – (ESC) approach .................................................. 53

iv

Appendix B. ICD-10-CM Diagnostic codes .................................................................. 54
Appendix C. IRB protocol ............................................................................................ 55
Appendix D. Classification criteria of Income Quartiles (AHRQ, 2008) ....................... 56
Appendix E. Healthcare Common Procedure Coding System ....................................... 57
Appendix F. Dummy variable representation for NICU utilization................................ 58
Appendix G. SAS codes ............................................................................................... 59
Appendix H. Correlations to assess potential collinearity among model predictors ....... 60
Appendix I. Bootstrapped chi-square outputs ................................................................ 61
Appendix J. Bootstrapped independent-samples t- test .................................................. 64
Appendix K. List of Acronyms ..................................................................................... 67
Appendix L. List of Definitions .................................................................................... 68
References ....................................................................................................................... 69
Curriculum Vitae ........................................................................................................... 90

iv

List of Tables
Table 1: Variables and statistical models for each research question .................................... 22
Table 2: Multilevel model building process ......................................................................... 23
Table 3: NAS rates per 1,000 births by different Nevada geographical units, 2016-2018 ..... 29
Table 4: NAS rates per 1,000 births by demographic and payer groups, 2016-2018 ............. 30
Table 5: Demographic characteristics NAS infants vs. healthy births, 2016-2018 ................ 31
Table 6: Clinical characteristics of NAS infants vs. healthy births, 2016-2018..................... 32
Table 7: Health resource utilization for NAS infants vs. healthy births, 2016-2018 .............. 33
Table 8: NICU use and hospital procedures (NAS infants vs. healthy births), 2016-2018 .... 35
Table 9: Aggregate hospital charges related to NAS vs. healthy births 2016-2018 ................. 1
Table 10: Multilevel model fit and hospital clustering statistics ........................................... 39
Table 11: Estimated odds ratio for multilevel logistic regression models ............................. 40

viii

List of Figures
Figure 1: NAS rate per 1,000 Newborn Hospitalizations in Nevada and the Nation ............. 25
Figure 2: NAS rate per 1,000 Newborn Hospitalizations (By Nevada region) ...................... 25
Figure 3: NAS rate per 1,000 among Newborn Hospitalizations (By County) ...................... 26
Figure 4: NAS rate per 1,000 Newborn Hospitalizations (By Race) ..................................... 27
Figure 5: NAS rate per 1,000 Newborn Hospitalizations (By Median Income) .................... 27
Figure 6: NAS rate per 1,000 Newborn Hospitalizations (By Expected Payer)..................... 28
Figure 7: Mean length of stay for NAS infants vs. healthy births, 2016-2018....................... 34
Figure 8: Health care cost for all NAS infants vs. healthy births, 2016-2018........................ 36

ix

Chapter 1. Introduction
Background
Neonatal abstinence syndrome (NAS) is a constellation of withdrawal symptoms,
manifested immediately after birth among babies of drug-dependent mothers, following
abrupt discontinuation of in-utero exposure to the drugs, including prescription or illicit
drugs (Hamdan, 2019; Hudak & Tan, 2012; Lisonkova et al., 2019; March of Dimes,
2017). The risk of withdrawal syndrome may also exist for critically ill or hospitalized
infants, who develop physical dependence on medications used for achieving analgesia and
sedation (Hudak & Tan, 2012). The latter is called neonatal iatrogenic withdrawal, which
occurs secondary to therapeutic exposure of the drugs used in the neonatal intensive care
units (NICU) (Crampton & Gruchala, 2013; Hall & Shbarou, 2009; Hudak & Tan, 2012).
The most common group of analgesics and sedatives used to treat chronic pain conditions
in mothers and infants are opioids and benzodiazepines, including morphine, fentanyl,
methadone, and midazolam (Hall & Shbarou, 2009). NAS and neonatal iatrogenic
withdrawal present a similar spectrum of symptoms, affecting mainly the central nervous
system, peripheral nervous system, and gastrointestinal system (Crampton & Gruchala,
2013; Logan, Brown, & Hayes, 2013; Finnegan, Hagan, & Kaltenbach 1991). Symptoms
include wakefulness, irritability (high-pitched cry), tremors, hypertonic muscles, diarrhea,
regurgitation (poor sucking reflex), difficulty breathing, and impaired weight gain (Logan
et al., 2013; March of Dimes, 2017; McQueen & Murphy-Oikonen, 2016). The symptoms
appear within the first few days after birth and are of variable severity (McQueen &
Murphy-Oikonen, 2016). The severity of NAS symptoms can be assessed by the Modified
Finnegan Scoring System (Logan et al., 2013; Finnegan et al., 1991).
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Diagnosis: The Finnegan scoring system, which is also called the Neonatal Abstinence
Scoring System (NASS), is a widely used diagnostic tool (Jones et al., 2016; McQueen &
Murphy-Oikonen, 2016). The tool was further modified by the American Academy of
Pediatrics (Hudak & Tan, 2012; McQueen & Murphy-Oikonen, 2016). This modified version
(Appendix A.1) is a 30-item questionnaire with score ranges from 0 to 44; scores equal or
greater than 8 are suggestive of NAS (Zimmermann-Baer, Nötzli, Rentsch, & Bucher, 2010).
Other assessment tools include the Narcotic Withdrawal Score (Lipsitz score) and the
Neonatal Narcotic Withdrawal Index (NWI) (Bagley, Wachman, Holland, & Brogly 2014;
Jones et al., 2016). The newer ESC (Eat, Sleep, Console) approach has been reported to be an
effective method of assessment to reduce the need of pharmacologic management with
subsequent decrease in length of hospital stay (Grossman, Lipshaw, Osborn, & Berkwitt
2017). The ESC approach identifies an infant not requiring further intervention if he or she
eats at least 1 ounce per feed, has undisturbed sleep for an hour, and is consolable (if crying)
within 10 minutes (Gross et al., 2017; Appendix A.2).
Treatment: NAS can be managed by non-pharmacological and pharmacologic interventions
(March of Dimes, 2017). The non-pharmacologic methods include rooming-in with the
mother, skin to skin contact (Kangaroo care), avoiding overstimulation by having a calm
environment, and encouraging breast feeding if not otherwise contraindicated (Bagley et al.,
2016; Hünseler, Brückle, Roth, & Kribs, 2013; March of Dimes, 2017). In addition, bed
type, positioning of the infant (Prone versus Supine), and non-insertive acupuncture (NIA)
were reported to be useful adjuncts to supportive care of drug-exposed infants (Bagley et al.,
2016; D'Apolito, 1999; Filippelli et al., 2012; Maichuk, Zahorodny, & Marshall, 1999; Oro,
1988). As compared to formula milk, breast milk was reported to decrease the severity of
NAS and need of pharmacologic treatment (Abdel-Latif et al., 2006; McQueen, MurphyOikonen). According to previous evidence, rooming-in was reported to be advantageous in
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decreasing the length of hospital stay as compared to the standard care in the hospital nursery.
Infants with rooming-in care were reported to have shorter hospital stays and were 60% less
likely to need opioid replacement (pharmacologic) therapy and admission to the NICU
(Abrahams et al., 2007). Among the bed types, non-oscillating water beds were beneficial in
consistent weight gain and decreased the need of opioid replacement therapy among NAS
infants (Oro, 1988). Opioid replacement therapy (pharmacologic intervention) is indicated
when the sum of three consecutive Finnegan scores is ≥ 24 (Bagley et al., 2016; Jackson,
Ting, McKay, Galea, & Skeoch, 2004; March of Dimes, 2017). The first line of medications
used to treat NAS infants is Ethanol-free Morphine solution of 0.4 mg/mL concentration
(Bagley, 2016; Kraft & van den Anker, 2012). However, evidence of the efficacy of this
approach is lacking and needs to be determined through prospective trials.
Description of the problem
The problem of maternal drug addiction has been prevalent since the 19th century; however,
the teratogenic potential of maternal substance use was not discovered until the first case of
congenital morphinism was reported in 1875 (Kocherlakota, 2014). Following this, several
cases of neonatal withdrawal secondary to maternal opioid use, including Buprenorphine and
Oxycontin, were reported between 1997-2002 (Kocherlakota, 2014). From 2000-2009, the
use of opiates among pregnant women increased from 1.19 to 5.63 per 1,000 births/year
(Patrick et al., 2013). As a result, an epidemic of NAS with a total of 21,732 infants, was
reported in 2012 (Patrick, Davis, Lehmann, & Cooper 2015). The incidence of NAS has
increased approximately 6-fold (1.20 to 6.7 per 1,000 hospital births/year; 450%) from 20002016 (Patrick et al., 2013; Patrick et al., 2015; Strahan et al., 2019). As a result, the health
care resource utilization associated with NAS has also increased. Reportedly, the average
length of hospital stays (LOS) of NAS infants was nearly 8 times that of non-NAS infants (16
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days vs. 2 days) in 2012 (Patrick et al., 2015). The LOS may extend by one more week to a
total of 23 days if the NAS is treated by pharmacologic methods (Patrick et al., 2015).
Likewise, there was a remarkable difference in the associated hospital charges of $66,700
($93,400 if treated pharmacologically) among NAS infants as opposed to $3,500 for nonNAS infants (Patrick et al., 2015). Furthermore, the aggregate hospital charges have also
increased significantly from $732 Million to $1.5 Billion from 2009-2013, with over 75% of
the charges attributed to Medicaid financed births (Patrick et al., 2013; Patrick et al., 2015).
In addition, the rate of NICU admissions quadrupled (7 to 27 per 1,000 admissions) with a
significant increase in the median length of NICU stay from 13 to 19 days between 20042013 in the U.S. (Tolia et al., 2016). NICU utilization by NAS infants has increased from
0.6% to 4% during the same period, which subsequently increased the health care burden
nationwide (Tolia et al., 2016).
According to a study of 28 states, state-wide trends in NAS incidence were consistent with
the previously reported national statistics in 1999-2013 (Ko et al., 2016; Patrick et al., 2013;
Patrick et al., 2015). There was a 300% (1.5-6.0 cases per 1,000 hospital births/year) increase
in overall state-wide (28 states) NAS incidence as compared to 383% (1.2-5.4 cases per 1,000
hospital births/year) nationally between 1999-2013 (Ko et al., 2016; Patrick et al., 2013;
Patrick et al., 2015). At the state level, significant variations in NAS incidence were observed
with an incidence as low as 0.7 cases per 1,000 births in Hawaii compared to an incidence of
33.4 cases per 1,000 hospital births in West Virginia (Ko et al., 2016).
These state-wide variations may be attributed to opioid prescribing rates and prevalence of
opioid use disorder among pregnant women (Haight, Ko, Tong, Bohm, & Callaghan, 2018).
For instance, West Virginia ranks third in opioid pain relievers (OPR) prescribing rates and
reported a prescribing rate of 137.6 prescriptions per 100 persons in 2012 (Paulozzi, Mack, &
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Hockenberry, 2014). In addition, the higher incidence of NAS in West Virginia can also be
partly explained by the elevated rates of opioid use disorder (OUD) among reproductive-aged
and pregnant women, which reached 30 cases per 1,000 delivery hospitalizations/year in
2014 (Haight et al., 2018; Ko et al., 2016). Similar increasing linear trends of OUD were
reported in all other states, for instance, in Nevada the prevalence of OUD increased from 0.6
to 4.5 from 2002-2014 (Haight et al., 2018). Nevada ranks 15th in prescribing OPRs and had a
consistently higher OPR prescribing rate than the national figures (94.1 prescriptions/100
persons in Nevada vs. 82.5 OPR prescriptions/100 persons nationally) in 2012 (Paulozzi et
al., 2014). Correspondingly, the incidence of NAS in Nevada has increased from 1.1 cases
per 1,000 births in 2003 to 4.8 cases per 1,000 births in 2013 (Ko et al., 2016). Previous
estimates of NAS were based on the International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) algorithm (Agency for Healthcare Research and Quality
[AHRQ], 2018). The ICD-9-CM coding was lacking the details necessary to differentiate
between the two categories of NAS; therefore, previous health and financial national and
state-wide estimates of NAS were provided after excluding the cases of presumed iatrogenic
or therapeutic exposures (diagnostic codes 765.00-765.05, 770.7, 772.10-772.14, 777.50777.53, 777.6 and 779.7) (Patrick et al., 2012; Patrick et al., 2015). Effective October 1,
2015, ICD-10-CM presents a better opportunity to delineate the two categories of NAS to
yield more precise estimates differentiated by presumed exposure.
While some data on NAS incidence in Nevada are available, there is a paucity of Nevada data
related to financial estimates of NAS. With the increasing rates of opioid prescriptions and
sequalae, such as NAS, in Nevada, it is essential to analyze the current incidence rates, health
care utilization patterns, and associated cost of NAS to design state-wide prevention efforts.
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Purpose of the study
The objectives of this study were to ascertain the statewide burden of NAS in Nevada from
2016 to 2018, including incidence rates, health care utilization patterns, associated health care
cost, and differences across demographic, clinical, and hospital-based characteristics between
newborns with and without a NAS diagnosis among all-payer (public, private, and selfinsured) pediatric patient discharges.
Significance of the study
This study will contribute to the literature on NAS by providing the most recent incidence
estimates, which are important to the formulation of public health plans and allocation of
health resources to improve the neonatal health outcomes in Nevada. In addition, the study
will report on the quantity of resources utilized in terms of proportion of hospital procedures,
days and admissions to the NICU, hospital LOS and associated cost estimates to assess the
financial impact of NAS in Nevada. Although national cost estimates are available, to our
knowledge, this is the first study to analyze the financial impact of NAS in Nevada.
Moreover, the implementation of the ICD-10-CM coding algorithm will allow more precise
estimates after making a sharp distinction between NAS secondary to maternal substance use
(diagnostic code P96.1) and NAS due to therapeutic exposure of pain-killers and sedatives
among critically-ill neonates (diagnostic code P96.2) (AHRQ, 2018). It is expected that the
results of this study will aid in the identification of clinical, demographic, and hospital-based
risk factors of NAS, and direct early intervention services to these drug exposed infants.
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Chapter 2. Literature review

NAS as a health and fiscal challenge
NAS poses a major global health and fiscal challenge, with increasing prevalence and rising
health care expenditures reported in countries such as England, Canada, and Australia
(Davies et al., 2015). In 2011, the highest prevalence rates of NAS were reported in Ontario,
Canada with 4.29/1,000 hospital births, followed by the U.S. rate of 3.6/1,000 hospital births
(Davies et al., 2015; Turner et al., 2015). In the U.S., NAS is a growing epidemic, with a total
of 25,213 NAS births in 48 states in 2016 (AHRQ, 2018). Geographic variations of NAS
incidence have been reported with the East South Central division (Kentucky, Tennessee,
Mississippi, Alabama) having an incidence of 16.2 per 1,000 hospital births, as compared to
the West South Central division (Oklahoma, Texas, Arkansas, Louisiana) with an incidence
rate of 2.6 (2.3-2.9) per 1,000 hospital births (Patrick et al., 2015). Health care resource
utilization and expenditure have also significantly increased (Filteau, Coo, & Dow, 2018;
Patrick et al., 2013). For instance, in Canada, the number of beds occupied per day associated
with NAS increased 3.5X from 19.7 beds to 69.4 beds between 2003-2014 (Filteau et al.,
2018). In addition, the total hospital charges associated with NAS increased by 77.7% ($11.8
to $20.3 million) during 2010-2014 in Canada. In the U.S., the actual health care cost (after
using cost-to-charge ratio) associated with NAS was reported to reach $316 million in 2012
(Corr & Hollenbeak, 2017). The average cost for treating a NAS infant in the U.S. was
$16,893 compared to $5,610 in non-NAS infants (Corr & Hollenback, 2017). These cost
estimates do not include the costs to treat long term complications of NAS, such as
behavioral/cognitive deficits, ear infections, lack of motor skills, and visual disturbances
(Maguire et al., 2016). Infants with a history of NAS are more likely to have educational or
intellectual disabilities (with subsequent lower academic achievements) and need special
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education services (Fill et al., 2018; Morgan & Wang, 2019). In Philadelphia, the total
annual education cost for infants with a history of NAS was estimated to be $1,012,506 in
2015, of which approximately $506,253 was attributed to supplying special classes to the
children (Morgan & Wang, 2019). These estimates represent NAS due to maternal use of
opioids only; the overall cost after including therapeutic NAS is probably higher.
NAS as a peril of maternal drug use
NAS results in approximately 75%-95% cases following maternal use of drugs during
pregnancy, which has also increased significantly over the past few decades (Hudak & Tan,
2012; Patrick et al., 2013). Between 1998-2011, the prevalence of maternal opioid use in the
U.S. increased by 127% (0.17% in 1998, 0.39% in 2011) (Maeda, Bateman, Clancy, Creanga,
& Leffert, 2015). Opioid-containing medications are most commonly prescribed to women of
reproductive age (15-44 years), with a higher prescription rate of 1.6 prescriptions per
Medicaid-enrolled women compared to 0.7 prescriptions per privately insured women in
2012 (Ailes et al., 2015). The prevalence of prescription opioid use among Medicaid-enrolled
women of reproductive age was higher as opposed to those privately insured (39.4% vs.
27.7%) (Ailes et al., 2015). The most widely prescribed opioid was hydrocodone, and rates of
prescriptions among non-Hispanic white women were nearly twice compared to nonHispanic black women (Ailes et al., 2015). Despite racial and ethnic differences in
prescribing trends, variations by urban-rural status also exist (Garcia et al., 2019). According
to recent analysis of the national electronic health record database, rural areas (particularly
nonmetropolitan counties) were reported to have higher opioid prescriptions compared to
urban areas (metropolitan counties) between 2014-2017 (Garcia et al., 2019). These
variations are attributed to limited availability of alternative medical treatments, less stringent
regulations to control opioid prescribing, and individual level relationships between providers
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and patients in the rural areas (Click, Basden, Bohannon, Anderson, & Tudiver, 2017; Keyes,
Cerdá, Brady, Havens & Galea, 2014; Monnat & Rigg, 2015). In 2012, prescribers in the
U.S. wrote 82.5 prescriptions per 100 persons for opioid pain relievers and 37.6 prescriptions
per 100 persons for benzodiazepines (Paulozzi et al., 2014). Statewide variations of
prescribing OPRs, benzodiazepines, and high dose OPRs were reported, with Nevada ranking
third in the Nation in prescribing high dose OPRs at a rate of 8.2 prescriptions per 100
persons (Paulozzi et al., 2014). Comparable prescribing rates of high dose OPRs were
reported in Delaware (8.8 prescriptions per 100 persons, rank 1 in the Nation) and Tennessee
(8.7 prescriptions per 100, rank 2) (Paulozzi et al., 2014). Opioid or drug-dependent mothers
were also 4.6X more likely to die during hospitalization (adjusted odds ratio [aOR], 4.6; 95%
CI, 1.8 to 12.1) (Maeda et al., 2015). The problem of overprescribing has surged over the past
few decades, which underscores the need for a multifaceted approach, including national,
state, and provider level strategies to reverse the opioid epidemic.
Efforts to reverse the opioid epidemic and legislative updates
Given the association between opioid overuse among pregnant women and NAS, it is critical
to implement prevention strategies to address the opioid crisis and promote favorable
maternal and infant health outcomes. In 2016, the Centers for Disease Control and Prevention
(CDC) provided guidelines for prescribing opioids for chronic pain management, which
requires clinicians to weigh the risks and benefits associated with opioid use before
prescribing to patients (Dowell, Haegerich & Chou, 2016). It also recommends clinicians to
manage chronic pain with nonpharmacologic and nonopioid pharmacologic methods unless
the expected benefits with opioid therapy outweigh the harms associated with it (Dowell et
al., 2016). If opioid pain relievers are to be prescribed, then immediate release opioids should
be preferred over extended release opioids (Dowell et al., 2016). These guidelines intend to
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improve the communication between clinicians and patients to raise awareness about the safe
and effective use of opioid analgesics. In 2016, the U.S. Surgeon General’s “Turn the Tide
Campaign” was introduced to encourage physicians to adopt CDC’s prescribing guidelines,
screening patients for potential opioid misuse, referring patients to appropriate evidence
treatment services, and viewing or treating addiction as a chronic illness rather than a moral
failing (American Academy of Family Physicians [AAFP], 2016).
State legislation has also been introduced to control substance use during pregnancy. For
example, 23 states consider substance use during pregnancy as a type of child abuse, and
Nevada is one of those states (Guttmacher Institute, 2019). Twenty-five states, including
Nevada, require reporting of suspected prenatal drug use by health care professionals, and 19
states have established or funded drug treatment facilities for pregnant women (Guttmacher
Institute, 2019). CDC has also developed the Opioid Use Disorder, Maternal Outcomes, and
Neonatal Abstinence Syndrome Initiative Learning Community (OMNI LC) in partnership
with the Association of State and Territorial Health Officials (ASTHO) to identify gaps in
providing perinatal care services (Kroelinger, et al., 2019). This initiative emphasizes 5
different core areas, namely access to quality services, providers’ education and training, data
monitoring and evaluation, financing and coverage, and ethical and legal, and social
considerations (Kroelinger, et al., 2019).
One of the promising tools, for which the potential has not yet been realized was the
Prescription Drug Monitoring Programs (PDMPs). PDMPs form a database through which a
prescriber can track the complete prescription history of a patient to have a better
understanding of a patient’s behavior and previous prescription records (CDC, 2019).
Enhancing the use of PDMPs is critical for careful and controlled opioid prescribing (CDC,
2019). The Comprehensive Addiction and Recovery Act (CARA), which was signed into law
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in 2016, requires the allocation of federal funds to set up substance use facilities for pregnant
women and establishing state PDMPs (American Society of Addiction Medicine, n.d.).
Currently, 49 states have operational PDMPs; however, their utilization is low (Haffajee,
Jena, & Weiner, 2015). Recently, the bill called “Prescription Drug Monitoring Act of 2019”
was introduced in the U.S. Senate. This bill requires prescribers from each PDMP operational
funded state to use PDMPs for searching a patient’s drug history prior to prescribing
Schedule II-IV controlled substances (Bureau of Justice Assistance, U.S. Department of
Justice, n.d.; National Alliance for Model State Drug Laws [NAMSDL], 2018).
Another important CDC consideration was to implement mandatory clinical reporting and to
set up state-wide surveillance systems for NAS (Warren et al., 2015). Previous estimates
were based on hospital administrative data, which may be associated with a substantial delay
before the data were available for analysis (Creanga et al., 2013; Patrick et al., 2012). With
the surging trends of NAS, it is critical to have cases clinically reported so that immediate
preventive strategies and policies can be formulated (Jilani et al., 2019). Although NAS was
added to all states’ reportable disease list in 2013, currently only six states (Arizona, Florida,
Georgia, Kentucky, Virginia, and Tennessee) have mandates for its clinical reporting (Jilani
et al., 2019). CDC views the clinical reporting approach as a promising avenue to analyze
timely estimates for directing prompt preventive measures to help reduce the burden of NAS.
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Chapter 3. Methods
Research questions
To determine the impact of Neonatal Abstinence Syndrome among all payer inpatient
pediatric discharges, we aimed to answer two descriptive/explorative research questions:
Question 1: What was the incidence rate of Neonatal Abstinence Syndrome in Nevada during
2016-2018, and how did it change over this time?
1a. What were the incidence rates of NAS across the two most populous counties
(Washoe vs. Clark) of Nevada?
Question 2: What were the risk factors associated with Neonatal Abstinence Syndrome?
2a. What were the neonatal risk factors associated with NAS?
2b. What were the hospital-based risk factors associated with NAS?
In addition, we aimed to address the following research questions and hypotheses.
Question 3: What were the health care utilization patterns associated with NAS in Nevada?
3a. Were there any significant differences in hospital utilization patterns among NAS
and non-NAS infants?
•

H01: There will be no difference in the length of hospital stay of NAS and non-NAS
infants in Nevada.

•

Ha1: The length of hospital stay will be longer among NAS infants compared to nonNAS infants in Nevada.

•

H02: There will be no difference in the proportion of hospital procedures performed
among NAS and non-NAS infants in Nevada.
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•

Ha2: The proportion of hospital procedures will be greater among NAS infants
compared to non-NAS infants in Nevada.

•

H03: There will be no difference in the proportions of NICU admissions among NAS
and non-NAS infants in Nevada.

•

Ha3: The proportions of NICU admissions will be greater among NAS infants
compared to non-NAS infants in Nevada.

•

H04: There will be no difference in the days spent in the NICU among NAS and nonNAS infants in Nevada.

•

Ha4: The NICU days will be greater among NAS infants compared to non-NAS
infants in Nevada.

Question 4: What were the health care expenditures associated with NAS in Nevada?
4a. Were there any significant differences in the health care costs between NAS and
non-NAS infants?
•

H0: There will be no difference in the health care costs of NAS and non NAS infants
in Nevada.

•

Ha: The health care costs of NAS infants will be higher compared to non-NAS infants
in Nevada.

Specific aims
•

To provide current incidence rates of NAS (2016-2018) to identify the magnitude of
NAS in Nevada. The variations in the NAS incidence across two major population
centers of Nevada, including Clark and Washoe counties will be crucial for regional
planning for the effective allocation of health resources where they are needed.
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•

To identify health care utilization patterns in the form of length of hospitalization,
NICU use, and the proportion of hospital procedures performed among NAS infants
in Nevada. These data will assist in understanding the current status of state-wide
health care delivery.

•

To perform an economic evaluation (i.e., hospital charges) of NAS in Nevada. This
information will be vital for prioritizing the state’s financial needs or challenges. It
will also help target prevention efforts on the high-cost aspect of NAS and to devise
cost-effective programs to curb the costs.

•

To assess resource utilization and associated hospital charges depending on the
payment source (public/private) to determine the burden on federally funded
programs, including Medicaid.

•

To identify risk factors to help target prevention efforts to high-risk groups.

•

To compare demographic and clinical characteristics of NAS and non-NAS infants.

Study design and setting
Using multiple cross-sectional analyses and de-identified hospital administrative data, this
geographically defined, state-wide, nested (within hospitals’ cluster) study aimed to collect
health statistics related to NAS from 2016 through 2018 in Nevada. Nevada ranks 33rd among
the most populous states in the United States, with a population over 3 million, of which
657,620 eligible Nevadans’ health insurance was financed by Medicaid in 2018 (Comlossy,
2018; U.S. Census Bureau, 2019). In 2016, the total Medicaid spending in Nevada was $3.36
billion (Centers for Medicare & Medicaid Services, 2017; Kaiser Family Foundation, 2017).
Most of the Nevada population is concentrated in Clark and Washoe counties (U.S. Census
Bureau, 2019). According to recent estimates, Las Vegas and Reno are the most populous
cities in Clark and Washoe counties, respectively (U.S. Census Bureau, 2019).
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Neonatal Abstinence Syndrome Standardized Case Definition

According to the Council of State and Territorial Epidemiologists (CSTE, n.d.) (tier 2 case
definition for identifying NAS cases in hospital administrative data), the criteria of
classifying confirmed and suspect NAS cases is as follows:
•

The confirmed case is a neonate with a billing diagnosis of the ICD-10 code of P96.1
(Appendix B) appearing in any of the diagnostic fields in the hospital administrative
data before 28 days of age.

•

The suspect case is a neonate without a billing diagnosis of ICD-10 code of P96.1
AND contains any diagnosis code of P0414, P0417, and P041A, indicating
maternal use of opiates, sedative-hypnotics or anxiolytics within the birth
hospitalization or a hospitalization (Appendix B) before 28 days of age.

Data source
This study used secondary data from a de-identified state administrative database (i.e., Center
for Health Information Analysis for Nevada [CHIA]). CHIA collects all hospital admission
discharge data for all licensed hospitals in Nevada and includes demographic information for
patients, procedures (25 fields), diagnostic codes (33 fields), revenue and service codes (60
fields), length of hospital stay, discharge status, and billing information (e.g., payer and
hospital charges) (CHIA, n.d). Analyses of these data were at the aggregate level and for
disease conditions in which n>10, (e.g., percentage of patients seen each year who were
diagnosed with Neonatal Abstinence Syndrome). Discharge records utilized in this research
were obtained through a Limited Data Use Agreement (LDUA) granted to the UNLV School
of Public Health and was considered an ‘excluded’ study per the UNLV Institutional Review
Board criteria (Appendix C).
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Data acquisition
The data were acquired in digital form. The information related to variables of interest was
collected (depending on availability) in CHIA’s data distribution dictionary (available at
https://www.chiaunlv.com/HealthFacilityData/DataDistributionFormats.php). The data were
available free of cost to Nevada state public entities, including UNLV researchers and
students.
Data storage and protection
Data were stored securely by password and analyzed using SAS software on a personal
computer at UNLV. Algorithms were written to extract relevant diagnoses/procedures using
ICD9/10, Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding
System (HCPCS) codes. Data were summarized in tables and graphs, and aggregated
population-based estimates were calculated if sample sizes were adequate. In compliance
with privacy guidelines, no patient-level data were released, and any report produced that
contained patient demographics and geographic location was aggregated.
Data Set
The population includes all newborn hospital (inpatient) discharge records of Nevada for the
years 2016-2018. Infants showing the ICD-10-CM code P96.1 appearing in any of 25
diagnostic fields were identified with NAS. The suspected cases of NAS without ICD-10-CM
code P96.1 and with codes, including P0414, P0417, and P041A were also searched (per
CSTE definition). As a reference (i.e., non-NAS/healthy) group, uncomplicated births were
identified using the ICD-10 code (Z38.00) assigned to “live-born infant.”
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Inclusion and Exclusion Criteria
Infants with drug withdrawal (ICD-10-CM P96.1) following maternal drug abuse were
included. The following records were excluded: infants with drug withdrawal following
therapeutic drugs used (ICD-CM- P96.2) and newborns affected by reactions and
intoxications from maternal opiates and tranquilizers used during labor and delivery (P04.0).
Measures

Demographic characteristics: Infants with a diagnosis of NAS were identified by the ICD10-CM code. Newborn demographic data, including gender, race/ethnicity, income quartile
of patient’s zip code, and location were collected. Race was classified as white, black,
Hispanic, American Indian/Alaska Native, and Asian or Pacific Islander (API). The median
household income was approximated to the patient zip code using the most recent (2019)
estimates of the American Community Survey (U.S. Census Bureau, 2018). The
classification criteria (according to 2019 estimates) for income quartiles (Q1-Q4) was
obtained from the Health Cost and Utilization Project (HCUP) database (AHRQ, 2008)
(Appendix D).
Patient location was categorized into large central metropolitan, medium metro, small metro,
and rural (includes micropolitan and noncore) according to the 2013 new county-level
scheme developed by the National Center for Health Statistics (NCHS) (CDC, 2019). Two
categories (micropolitan and noncore) were combined into a single rural category to preserve
the results when sample sizes were small (n<10). Primary payer information was categorized
as public (Medicaid), private, and uninsured, which included self-pay and no charge.
Newborn clinical characteristics and hospital procedures: Ten clinical characteristics (i.e.,
prematurity, low birth weight, transient tachypnoea, meconium aspiration syndrome,
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respiratory problems, respiratory distress syndrome, neonatal jaundice, feeding difficulties,
seizures, and sepsis) were examined. These characteristics were a priori selected based on
published literature (Kallen et al., 2004; Lind et al., 2015; Winkelman et al., 2018; Appendix
B). Hospital procedures to diagnose and treat respiratory, gastrointestinal, and central nervous
system symptoms (that commonly occur in NAS infants) were also examined for the
frequency across the sample population. The ICD-10 medical/procedure, CPT, and HCPCS
codes (Appendix E) were used to define clinical conditions of infants (Appendix B). The
algorithm for identifying complex chronic conditions (CCC) was adapted from a previous
study (Feudtner, Feinstein, Zhong, Hall, & Dai, 2014).
Neonatal and hospital-based risk factors:

Demographic and clinical characteristics of

newborns (described above) and hospital-level factors, such as hospital academic status
(teaching hospital vs. non-teaching hospital), hospital location (rural vs. urban), and hospital
bed size (≤100, 101-299, ≥300) were examined as predictors of developing NAS (outcome).
The categorization of hospital factors was adapted from previous studies (Austin & Merlo,
2017; Young et al., 2019).
Health care utilization and cost: Five measures, LOS, admission to the NICU, days in the
NICU, proportion of hospital procedures, and total hospital charges were collected.
Outcomes

Incidence rates of NAS (with 95% confidence intervals) were calculated by year as the rate of
NAS diagnoses per 1,000 delivery hospitalizations. Overall rates (with 95% confidence
intervals) are presented by sex, payer source, median household income, and patient location.
In accordance with the data use agreement, any sample with n<10 was suppressed to preserve
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confidentiality. Descriptive statistics for demographic characteristics, payer source, and
clinical characteristics were generated for newborns with and without a diagnosis of NAS.
The NAS dependent variable was re-coded into a binary variable indicating presence
(NAS=1) or absence of NAS (NAS=0) for the multilevel logistic regression model to identify
predictors between NAS affected newborns and non-NAS births.
For health care utilization and cost, the main outcomes were mean length of hospital stay
LOS, NICU days (derived from the LOS for those admitted to the NICU), rate of NICU
admissions, proportion of hospital procedures, and inflation-adjusted cost. The NICU use for
each newborn was determined using the Universal Billing (UB)-92 revenue codes 174x,
173x, 172x, and 171x. The NICU category was created on the basis of level of service
indicated by UB-92 revenue codes in hierarchical manner with the highest being level 4
(most acute care, 174x) and the lowest being level 1 (newborn nursery care) (Centers for
Medicare and Medicaid Services, 2011; Noridian Healthcare Solutions, 2018; Parlett et al.,
2019). If a discharge record indicated that the patient had multiple revenue codes for the
NICU, then the highest level of service was included after excluding the relatively lower
levels to have four mutually exclusive categories of level of NICU utilized being expressed as
dummy variables with 0 as “no admission to a particular level” and 1 as “admission to a
particular level” (Appendix F). The calculation of NICU days assumed that babies were
transferred to the NICU within 24 hours of birth.
For health care cost, total hospital charges (adjusted for inflation to 2019 U.S. dollars) were
determined using the medical care component of the Consumer Price Index (Health
Resources and Services Administration [HRSA], 2019). Total charges reflecting the total
facility fee reported for each discharge record (not including professional fees) was
calculated. A detailed statistical plan is shown in Table 1.
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Statistical Analysis
A secondary analysis of hospital administrative data was conducted. The unit of analysis was
the newborn discharge/admission (in-patient) record. All statistical procedures utilized SAS
software version 9.4 (SAS Institute Inc., Cary, NC). The incidence rate was determined
arithmetically by dividing NAS-related newborn hospitalizations by the total number of
newborn hospitalizations (with conversion to number/1000) (Table 1). The chi-square (χ2)
test was used for conducting comparisons of categorical variables. The follow-up
contingency table analysis (post-hoc) was conducted to obtain p-values corresponding to
multilevel variables. The observed p-values were Bonferroni-corrected in multiple
comparisons to prevent type 1 errors (Beasley & Schumacker, 1995). The Bonferroni
correction was obtained by dividing the actual p-value obtained in the analysis and
multiplying it by the number of tests performed (Beasley & Schumacker, 1995). The
calculated p-values were then compared to a standard alpha level (0.05) to determine
statistical significance. P-values less than 0.05 were considered statistically signiﬁcant and
data were reported as 95% confidence intervals. Continuous variables are presented as the
mean ± standard deviation. Categorical variables were reported as percentages.
For continuous measures, including health care utilization measures (LOS, NICU days, and
total charges), the groups were compared using the independent-samples t-test. A follow-up
bootstrap analysis was conducted to validate statistical significance and to compare with the
classical estimates obtained through chi-square tests and independent-samples t-tests
(Thompson, 2014). The bootstrap estimates were compared with the classical estimates to
investigate replicability and consistency.
For investigating potential predictors of NAS, a multilevel (2-level) logistic regression
analysis was conducted to account for clustering of the patients within higher-level units
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(i.e., hospitals). This was done to have a better understanding of the underlying heterogeneity
of the data across hospital clusters. Multilevel modelling was conducted using the
GLIMMIX procedure in SAS (Appendix G). In the multilevel model building process, three
models were built to find the best fit (Table 2). The first was the null or unconditional model,
which did not contain any patient or hospital characteristics. This incorporated only hospital
specific random effects to model between hospital variation in terms of NAS status. The
intraclass correlation coefficient (ICC) was manually calculated from random intercept
variance and the standard logistic distribution (random intercept variance/random intercept
variance + 3.29 [standard logistic distribution]) to quantify the hospital-clustering effect
(Austin & Merlo, 2017). In other words, ICC was used to estimate the amount of variation in
the NAS status (outcome variable) between hospitals (clusters). ICC ranges from 0 to 1 and
this indicates the amount of variance in NAS attributable to patients (level-1) and hospitals
(level-2) (Austin & Merlo, 2017; Pozo-Rodriguez et al., 2015). The second model included
all patient-related (level 1) variables as fixed effects with hospital-specific random intercept
only to examine the relationship between these variables and incidence of NAS. A
correlation matrix for all independent (level 1) variables included in the second model was
calculated and examined for detecting multicollinearity (sharing variability) (Midi, Sarkar, &
Rana, 2010) (Appendix H). Upon detection of collinearity between two variables, only one
variable was included in the model. The third model included both patient characteristics and
hospital characteristics in addition to hospital-specific random effects (Table 2). Risk
estimates were shown as odds ratios, which were obtained by exponentiating the estimated
regression coefficients (Austin & Merlo, 2017).
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Table 1: Variables and statistical models for each research question
Question
Incidence of
Neonatal
Abstinence
Syndrome in
Nevada during
2016-2018

Risk factors
(neonatal and
hospital
based)

Main outcome
• NAS cases per
1,000 admissions
(diagnosis code
96.1)

Study measures
Variables
• Count variable:
Numerator (number
of events or number
of cases)
• Population variable:
Denominator (sum of
the populations for all
the years, 20162018).

• NAS as a binary
variable (NAS = 1
[present], NAS = 0
[absent])

•
•
•

Health care
utilization

• Length of stay
(LOS)
• NICU admissions
• NICU days
• Proportion of
hospital
procedures

•
•
•

Level-1 variables
(Patient related) a
Level 2 (or hospital
level) b predictors
Provider ID was used
as a level -2
identification
variable.
All NAS infants
Healthy newborns
Dependent variable:
LOS

Statistical Analysis
•

Crude incidence rate
= Number of new
NAS cases per 1,000
hospital births

•

Incidence by gender,
race, payer, patient
location, income
quartile

•

95% Confidence
intervals
Multilevel logistic
regression modelling
(GLIMMIX
procedure)
Risk estimate: Odds
ratio
Significance level: P
value < 0.05
Chi-square test
(classical
+bootstrap)
Frequency of
hospital procedures
and NICU use
Independent-samples
t-test (classical +
bootstrap)
Significance level:
P- value < 0.05
Bonferroni adjusted
p-values for multiple
comparisons
Independent-samples
t-test (classical +
bootstrap)
Significance level: P
value < 0.05

•

•
•
•
•
•
•
•

Health care
cost

a.

b.

• Inflation adjusted
total charges
(facility fee not
including
professional fees)

•
•
•

All NAS infants
Healthy newborn
Dependent variable:
Total charges

•
•

Gender, race, low birth weight, neonatal jaundice, transient tachypnoea, seizures, respiratory distress
problems, respiratory difficulties, feeding difficulties, sepsis, and meconium aspiration syndrome
(MAS).
Hospital academic status (teaching hospital vs. non-teaching hospital), Hospital location (rural vs.
urban) & hospital bed size (≤100, 101-299, ≥300).
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Table 2: Multilevel model building process
Model
Model 1
Model building process
Method
No predictors, just
random effect for the
intercept

Model 2

Model 3

Model 1 + level-1 fixed
effectsa

Model 2 + level-2
predictorsb

a. Level-1 (patient) factors: Gender, race, low birth weight, neonatal jaundice, transient
tachypnoea, seizures, respiratory distress problems, respiratory difficulties, feeding
difficulties, sepsis, and meconium aspiration syndrome (MAS).
b. Level-2 (hospital) factors: Hospital academic status (teaching hospital vs. non‐teaching
hospital), Hospital location (rural vs. urban) & hospital bed size (≤100, 101-299, ≥300).
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Chapter 4. Results
The study population consisted of 100,845 newborns discharged from 18 Nevada hospitals
during the years 2016-2018. The number of pediatric patients treated per hospital ranged
from 224 to 15,542, with a median of 3,762 (25th-75th percentile: 1,466-9,121). The binary
outcome for this study was the presence of NAS, which occurred for 796 (0.8%) in the
population.

Incidence

During the study period (2016-2018), the overall incidence of NAS was nearly 8 per 1,000
hospital births (95% CI 7,9) in Nevada, which is 1.7X the rate previously reported in 2013
(Figure 1, Table 3). Prior to 2016, the incidence rates of NAS in Nevada were slightly lower
than the national rates (Figure 1). However, in 2016, the incidence of NAS in Nevada was
nearly 23% greater compared to the national incidence reported (8.6 per 1,000 hospital births
vs. 7 per 1,000 hospital births; Figure 1). This trend reversal was observed for the year 2016,
in which the more specific ICD-10 codes for identifying NAS cases (secondary to maternal
drug abuse and neonatal iatrogenic withdrawal) became available. Additional national data
for subsequent years (2017 and 2018) will be needed to verify if this change was due to the
absolute increase in the incidence or may have resulted from improved identification of NAS
cases. The overall NAS incidence varied across different regions, with Southern Nevada
having the highest incidence rate of 8.2 (95% CI 8,9) per 1,000 hospital births compared to
other regions (northern, Washoe, and rural) (Figure 2, Table 3). In 2016, 78% of NAS cases
diagnosed in Nevada were residents of Clark County (230 NAS cases in Clark vs. 292 in
Nevada; Table 3). From 2016 to 2018, the incidence rates declined slightly in Clark County,
whereas Washoe County showed increasing trends (Figure 3). In 2016, the incidence of NAS
in Henderson was the highest among other Nevada cities, and then decreased by nearly 33%
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in the following 2 years (Table 3). In the most recent study year (2018), Henderson still had
the greatest incidence rate among Nevada cities (i.e., 9.7 per 1,000 hospital births) followed
by Reno, North Las Vegas, and Las Vegas (Table 3).
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Figure 1: NAS rate per 1,000 Newborn Hospitalizations in Nevada and the Nation
Note: no national data are available for 2017-2018
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Figure 2: NAS rate per 1,000 Newborn Hospitalizations (By Nevada region)
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Figure 3: NAS rate per 1,000 among Newborn Hospitalizations (By County)

Among different demographic groups, the overall (2016-2018) incidence of NAS was the
highest among white newborns, occurring at a rate of 12 per 1,000 hospital births (95% CI
11,13) (Figure 4, Table 4). The incidence of NAS among white infants decreased after 2016;
however, a trend reversal was observed among API infants. The incidence of NAS increased
from 0.9 to 3.8 per 1,000 newborn hospitalizations among API infants from 2016 to 2018.
There were no differences in the overall incidence rates by gender. NAS rates also varied by
income zip quartile, with infants born in areas of the lowest quartile with median household
income of ≤ $47,699, having the highest overall incidence of NAS of 12.8 (95% CI 8,13) per
1,000 hospital births (Figure 5). In terms of geography, the NAS incidence rate was highest
in large central metropolitan areas, and lower but comparable among rural and small/medium
metropolitan areas (Table 4). Rates differed by expected payer source, with Medicaidinsured births having the highest NAS incidence of 13.2 (95% CI 11,15) per 1,000 hospital
births, and 77.4% (616 out of 796) of NAS births financed by Nevada Medicaid in 20162018 (Figure 6, Table 4).
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Figure 4: NAS rate per 1,000 Newborn Hospitalizations (By Race)
API=Asian Pacific Islander; Native AA= Native Alaskan American
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Table 3: NAS rates per 1,000 births by different Nevada geographical units, 2016-2018
Geographical unit

Number of NAS cases

Rate per 1,000 hospital
Overall Rate
birthsa
per 1,000
(95% Confidence interval)

2016

2017

2018

2016

2017

2018

(2016 – 2018)

292

247

257

8.6
(8,10)

7.5
(7,8)

7.7
(7,9)

8.0
(7,9)

Southern Nevadab

234

194

192

Northern Nevadac

12

12

10

Washoed

34

33

39

Rural Nevadae

NRf

NR

NR

9.1
(8,10)
7.1
(5,17)
6.5
(4,9)
4.1
(-1, 9)

7.8
(7,9)
7.1
(3,11)
6.6
(4,9)
2.4
(-1,6)

7.7
(7,9)
7.2
(4,12)
7.5
(5,10)
5.3
(0,10)

8.2
(8,9)
7.1
(5,9)
6.8
(6,8)
4.0
(1,6)

Clark

230

191

190

Washoe

34

33

39

Othersg

20

18

23

9.1
(8,10)
6.5
(4,9)
7.0
(4,10)

7.8
(7,9)
6.5
(4.9)
6.0
(3,9)

7.7
(7,9)
7.5
(5,10)
7.9
(5,11)

8.2
(8,9)
6.8
(6,8)
7.0
(5,9)

Statewide (Nevada)
Region name

County name

City name
8.0
8.6
7.6
7.4
(7,9)
(7,10)
(6,9)
(6,9)
11.6
15.0
10.0
9.7
Henderson
43
29
27
(9,14)
(11,20)
(6,14)
(6,13)
6.4
5.6
6.0
7.5
North Las Vegas
18
18
23
(5,8)
(3,8)
(3,9)
(4,11)
7.3
7.6
6.4
8.0
Reno
26
21
27
(6,9)
(5.11)
(4,9)
(5,11)
5.5
5.0
6.9
5.0
Sparks
NR
NR
NR
(3,8)
(1,9)
(2,11)
(1,9)
a. The rates do not include suspect cases (n<10). The suspect case is a neonate without a billing diagnosis
of ICD-10 code of P96.1 diagnosis AND contains any diagnosis code of P0414, P0417, and P041A,
indicating maternal use of opiates, sedative-hypnotics or anxiolytics within the birth hospitalization or a
hospitalization before 28 days of age
b. Southern Nevada: Clark, Esmeralda, and Nye counties
c. Northern Nevada: Carson City, Churchill, Douglas, Lyon, Mineral and Storey counties
d.
Washoe region: Washoe county
e. Rural Nevada Region: Elko, Eureka, Humboldt, Lincoln, Pershing, and White Pine counties
f. Not reported due to low volume of NAS cases (n<10)
g. Other counties: Carson City, Churchill, Douglas, Elko, Esmeralda, Humboldt, Lincoln, Lyon, Mineral,
Nye, Pershing, Storey, and White Pine
Las Vegas

164

140

137

29

Table 4: NAS rates per 1,000 births by demographic and payer groups, 2016-2018
Group criteria

Number of NAS cases

Rate per 1,000 hospital births

Overall Rate
per 1,000
(95% Confidence interval)

2016

2017

2018

2016

2017

2018

(2016 – 2018)

Male

141

133

133

Female

149

114

124

8.2
(7,10)
8.9
(8,10)

7.8
(7,9)
7.0
(6,8)

7.8
(7,9)
7.6
(6,9)

8.0
(7,9)
8.0
(7,9)

White

217

161

172

Black

30

29

25

14.0
(12,16)
7.0
(5,9)

11.0
(9,13)
6.5
(4,9)

11.0
(9,13)
5.4
(3,7)

12.0
(11,13)
6.2
(5,8)

Hispanic

21

25

24

Asian Pacific
NRa
NR
Islander
Urbanization level of residence

NR

2.5
(1,4)
0.9
(-0.1,2)

3.3
(2,5)
3.0
(1,5)

3.8
(2,5)
3.8
(1,6)

3.1
(2,5)
2.5
(1,4)

Large central
metrob
Medium metroc

230

191

190

34

33

39

Small metrod

NR

NR

NR

Rural e

16

12

16

9.1
(8,10)
6.5
(4,9)
5.5
(-1,10)
7.9
(4,12)

7.8
(7,9)
6.5
(4,9)
5.0
(-1,10)
5.5
(2,9)

7.7
(7,9)
7.5
(5,10)
3.7
(-1,9)
7.6
(4,11)

8.2
(8,9)
6.8
(4,9)
6.3
(2,10)
6.9
(5,9)

14.0
(12,16)
48
39
51
3.2
(2,4)
Uninsured f
15
11
16
6.1
(3,9)
a. Not reported due to low volume of NAS cases (n<10)

13.0
(11,15)
2.6
(2,3)
3.7
(2,6)

12.7
(11,14)
3.3
(2,4)
5.4
(2,6)

13.2
(11,15)
3.1
(2,4)
5.0
(2,6)

Gender

Race

Payer source
Nevada
Medicaid
Private

229

197

190

b.
c.
d.
e.

Large central metro: Clark
Medium Metro: Washoe & Storey
Small metro: Carson City
Rural: The two categories of micropolitan (Churchill, Douglas, Elko, Eureka, Humboldt, Lyon, Nye) and
noncore (Esmeralda, Lander, Lincoln, Mineral, Pershing, White Pine) were combined into a single rural
category to preserve the results when sample sizes were small.
f. Uninsured payer category includes self-pay and no charge.
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Demographic and Clinical characteristics

Among 796 infants diagnosed with NAS and 100,049 other hospital births, the proportion of
male and female infants was comparable among NAS and healthy newborns (48.9% females
vs. 48.6%; p=0.6; p

boot=0.91;

Table 5). Compared to healthy newborns, NAS infants were

significantly more likely to be white (69.1% vs. 45.9%; p<0.00001), living in the zip codes
with the lowest median income (10.5% vs. 6.6%; p<0.0001), and were Medicaid-insured
(77.4% vs. 46.6%; p=0.00004; Table 5).

Table 5: Demographic characteristics NAS infants vs. healthy births, 2016-2018
Infants with Neonatal Abstinence Syndrome

All Other Hospital Births

N = 796

N = 100,049
%

p-valuea

N

%

N

Female

387

48.9

48,933

48.6

Male

407

51.1

50,991

51.1

Race
White

550

69.1

45,966

45.9

<0.00001

Black

84

10.6

13,425

13.4

0.02

Hispanic

70

8.8

22,491

22.5

<0.00001

b

API

18

2.3

7,021

7.0

<0.00001

Other

72

9.0

10,550

10.6

0.3

Private

138

17.3

45,096

45.1

<0.00001

Medicaid

616

77.4

46,604

46.6

0.00004

Uninsured
Income quartile
≤$47,999 (Q1)
$48,000-$60,999 (Q2)
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5.3

8,349

8.3

0.001

80
389

10.5
51.1

6,267
47,521

6.6
50.3

<0.00001
0.6

$61,000-$81,999 (Q3)
275
36.1
≥$82,000 (Q4)
17
2.23
a. The observed p-values were Bonferroni corrected
b. Asian or Pacific Islander

37,616
3,003

39.8
3.1

0.03
0.1

Demographics
Gender
0.6

Insurance
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Health outcomes for NAS infants were significantly worse than for all other Nevada infants.
Infants with NAS were more likely than other hospital births to have complications,
including neonatal jaundice (44.8% vs. 14.7%; p <0.001), prematurity (24.5% vs. 9.1%; p
<0.001), feeding difficulty (19.0% vs. 2.4%; p <0.001), respiratory distress syndrome (17.3%
vs. 6.0%; p <0.001), and transient tachypnoea of newborn (26.4% vs. 3.2%; p <0.001; Table
6). The frequencies and proportions obtained from classical chi-square analysis (Tables 5 and
6) were comparable with the bootstrap estimates obtained from 1000 random samples (with
replacement) drawn from the population (Appendix I.1 & I.2).

Table 6: Clinical characteristics of NAS infants vs. healthy births, 2016-2018
Infants with Neonatal Abstinence Syndrome
N = 796

All Other Hospital Births
N = 100,049

N

%

N

%

p-valuea

Neonatal Jaundice

357

44.8

14,695

14.7

<0.001

Prematurity

195

24.5

9,114

9.1

<0.001

Feeding Difficulty

151

19.0

2,408

2.4

<0.001

RDS

138

17.3

5,991

6.0

<0.001

Transient Tachypnoea

126

26.4

3,219

3.2

<0.001

Sepsis

76

9.5

2,341

2.3

<0.001

Low birth weight

73

9.2

3,199

3.2

<0.001

Clinical Characteristics

b

a.
b.

Indicates statistical significance if p-value<0.05.
Respiratory distress syndrome
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Health care utilization patterns

During the study period (2016-2018), mean LOS for newborns diagnosed with NAS was
significantly longer compared to newborns without NAS (17 days, SD=14 vs. 2.6 days,
SD=5, P<0.001, Figure 7, Table 7).

Table 7: Health resource utilization for NAS infants vs. healthy births, 2016-2018
Year

2016
(Mean ± SD)
Neonatal Abstinence Syndrome
Number of patients
292
Mean Length of Stay
17.2 ± 14.5
(days)
NICUa days
18.5 ± 14.5
Uncomplicated Births
Number of subjects
33,759
Mean Length of Stay
2.7 ± 5.5
(days)
NICU days
10.8 ± 14.3
a. Neonatal intensive care unit

2017
(Mean ± SD)

2018
(Mean ± SD)

2016 - 2018

247
17.6 ± 13.0

257
16.0 ± 14.0

796
17.0 ± 14.0

18.5 ± 12.8

17.5 ± 14.5

18.2 ± 14.0

33,060
2.6 ± 5.0

33,230
2.6 ± 4.8

100,049
2.6 ± 5.0

10.8 ± 13.0

10.5 ± 12.6

10.7 ± 13.4
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20
18

17.6

17.2

16

Mean length of hospital stay

16
14
12
10
8
6
4

2.7

2.6

2.6

2
0
2016

2017

2018

Year
NAS

Uncomplicated Birth

Figure 7: Mean length of stay for NAS infants vs. healthy births, 2016-2018

NICU utilization and frequency of hospital procedures: Infants with NAS were more likely
than other hospital births to utilize level 2 (13.0% vs. 1.2; p <0.001), level 3 (57.6% vs. 6.3; p
<0.001), and level 4 intensive neonatal care (21.4% vs. 5.7; p <0.001) (Table 8). Moreover,
NAS infants were more likely than other hospital births to undergo complicated hospital
procedures, including ventilation support (13.3% vs. 4.0%; p <0.001), infusion of nutritional
substances (11.9% vs. 2.5%; p <0.001), insertion of feeding device and resection of parts of
gastrointestinal tract (3.1% vs. 0.6%; p <0.001), and phototherapy of the skin (21.7% vs. 7.3;
p<0.0001) (Table 8). The proportions and p-values obtained from classical chi square (Table
8) were comparable with the bootstrap estimates obtained from 1000 random samples drawn
(with replacement) from the population (Appendix I.3).
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Table 8: NICU use and hospital procedures (NAS infants vs. healthy births), 2016-2018
Infants with Neonatal Abstinence Syndrome
N = 796
N
%
NICUb utilization
Level 1
Level 2
Level 3c
Level 4c
Respiratory
Ventilation Support
Endotracheal intubation
repair of diaphragm, and sternum
Gastrointestinal
Insertion of feeding device, repair
of esophagogastric junction
Drainage of stomach, pleural, and
peritoneal cavity with drainage
device
Infusion and Transfusion
Infusion of nutritional substance
Insertion of infusion device
Other procedures
Phototherapy of skin

All Other Hospital Births
N = 100,049
N
%
p-valuea

63
104
459
170

8.0
13.0
57.6
21.4

86,825
1,166
6,318
5,740

86.7
1.2
6.3
5.7

<0.0001
<0.0001
<0.0001
<0.0001

106
47

13.3
6.0

3,922
1,991

4.0
2.0

<0.0001
<0.0001

25

3.1

582

0.6

<0.0001

13

1.6

237

0.2

<0.0001

95
38

11.9
4.8

2,524
1,646

2.5
1.6

<0.0001
<0.0001

173

21.7

7,345

7.3

<0.0001

a. Indicates statistical significance when p-value <0.05
b. Neonatal intensive care unit
c. Level 3 & 4 (for critically ill babies). Additional information can be found at
https://www.marchofdimes.org/baby/levels-of-medical-care-for-your-newborn.aspx
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Health care cost

In the most recent study year (2018), inflation-adjusted mean hospital charges were
significantly higher for newborns diagnosed with NAS compared to unaffected newborns
($75,754, SD=66,450, 95% CI $65,974-$85,533 vs. $11,673, SD=40,174, 95% CI $11,195$12,152, P<0.001, Figure 8). Bootstrap estimates were comparable with the classical
estimates (Appendix J.1). The bootstrap histogram of mean differences in the length of stays
and health care costs showed normally distributed data (Appendix J.2 & J.3) which indicates
that the bootstrap estimates were similar to the classical parametric estimates. Through all
study years, most hospital charges were attributed to Nevada Medicaid programs, with more
than 3/4th of the total charges paid by state Medicaid. On average, this amounts to $11.8

Inflation adjusted health care cost (amount ± SD)

million of the total health care cost of $14.8 million between 2016 and 2018 (Table 9).

NAS
$90,000
$80,000

$76,960 ± 69,289

Uncomplicated Birth
$82,610 ± 66,985
$75,754 ± 66,450

$70,000
$60,000
$50,000
$40,000
$30,000
$20,000

$10,882 ± 43,661

$11,026 ± 48,586

$11,673± 40,174

$10,000
$0
2016

2017

2018

Year

Figure 8: Health care cost for all NAS infants vs. healthy births, 2016-2018
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Table 9: Aggregate hospital charges related to NAS vs. healthy births 2016-2018
Year

2016
Total Charges
($)

NAS births
Private
2,826,995
Medicaid
13,074,141
Self-pay
414,474
Total
16,315,611
All hospital births
Private
132,085,357
Medicaid
182,746,961
Self-pay
18,665,078
Total
333,497,396

SD

2017
Total Charges
($)

SD

2018
Total Charges
($)

SD

p-value

60,385
71,931
44,857
69,289

2,312,798
11,756,758
221,929
14,291,486

76,015
65,524
30,131
66,985

2,479,899
10,553,322
602,446
13,635,668

69,129
67,197
41,657
66,488

<0.001
<0.001
<0.001
--

45,218
54,408
37,784
137,410

124,757,061
179,097,978
19,564,466
323,419,505

40,215
50,006
27,617
117,838

148,095,334
162,605,450
19,483,438
330,184,222

41,712
42,783
18,865
103,360

<0.001
<0.001
<0.001
--
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Predictors
Interpretation of fitted multilevel logistic regression model: In the first unconditional model,
the intraclass coefficient (ICC) (calculated by the random intercept variance and the standard
logistic distribution, Table 10) was 6.5%, which indicates the fraction of the variability in
NAS incidence that is attributed to the hospitals in this study, leaving 93.5% of the
variability in the NAS incidence to be accounted for by the patients (Austin & Merlo, 2017;
Bell, Ene, Smiley, & Schoeneberger, 2013). A non-zero value of ICC (Table 10) indicates
presence of a clustering effect. Model 3 (with level-1 & level-2 predictors) appeared to be
the best fit, given the progressively decreasing values of Akaike and Bayesian information
criteria as progression occurred from model 1 through model 3 (Bell et al., 2013; Table 10).

In the model that included both patient and hospital characteristics (Model 3; best fit), seven
of the 12 patient characteristics and none of the hospital characteristics were significantly
associated with the odds of developing NAS (Table 11, [Model 2]). The remaining five
patient level factors (i.e., gender, low birth weight, meconium aspiration syndrome,
respiratory problems, and respiratory distress syndrome) were not statistically significant.
White infants were nearly 6 times more likely to have NAS compared to black infants (OR
6.16 vs. 1.64, Table 11). The Medicaid insured infants were 2.8 times (OR 2.88; 95% CI
1.98-4.2) more likely to have NAS compared to those uninsured (Table 11). NAS infants had
higher odds of developing transient tachypnoea, seizures, neonatal jaundice, feeding
difficulties, and sepsis compared to healthy hospital births (Table 11). None of the hospital
characteristics, including bed size, location (rural/urban), status (teaching/non-teaching), and
type (private/public) were statistically significant (Table 11).
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Table 10: Multilevel model fit and hospital clustering statistics
Model
Output
significance

Model 1
Random intercept
variance for ICCa

Model fit statistics
AICb
9179.62
c
BIC
9181.29
Hospital clustering statistics
ICC
0.065 (6.5%)

Model 2
Results indicate the
relationship between
level-1 predictors and
NAS

Model 3
Results indicate
cluster-specific
associations

4860.87
4880.87

4792
4813

a. Intraclass coefficient was calculated manually, Formula of ICC: random intercept
variance /random intercept variance + 3.29 (3.29 is the standard logistic distribution);
random intercept variance .2295 (model 1)
b. Akaike’s information criterion used to examine model fitness. The progressive decreasing
values (from model 1 to model 3) of BIC indicate improvement in model fitness.
c. Bayesian information criterion used to examine model fitness. The progressive decreasing
values of BIC (from model 1 to model 3) indicate improvement in model fitness.

39

Table 11: Estimated odds ratio for multilevel logistic regression models
Variable
Model 2
Patient characteristics
Female
Male
Race
Hispanic
White
Black
Asian or Pacific islander
Payer
Self-pay/uninsured
Private
Nevada Medicaid
Comorbidities
Feeding difficulty
Neonatal Jaundice
Seizures
Transient Tachypnoea
RDSb
Sepsis
Meconium Aspiration
Syndrome
Respiratory problems
Low birth weight

Odds ratioa (95% Confidence Interval)
Model 3

Reference
0.97 (0.83-1.13)

Reference
0.97 (0.83-1.15)

Reference
6.69 (5.12-8.74)
1.73 (1.24-2.39)
1.32 (0.77-2.24)

Reference
6.16 (4.67-8.14)
1.64 (1.17-2.30)
1.22 (0.71- 2.11)

Reference
0.56 (0.37-0.83)
2.87 (1.97-4.17)

Reference
0.54 (0.36-0.81)
2.88 (1.98-4.20)

4.60 (3.70-5.71)
3.30 (2.75-3.96)
2.9 (1.25-6.73)
2.5 (1.95-3.10)
1.12 (0.87-1.43)
1.65 (1.20-2.25)
1.00 (0.28-2.40)

4.54 (3.64-5.65)
3.32 (2.76-3.99)
2.96 (1.27-6.86)
2.43 (1.92-3.07)
1.11 (0.86-1.42)
1.67 (1.22-2.28)
0.98 (0.28-2.40)

0.53 (0.22-1.27)
0.97 (0.70-1.35)

0.53 (0.23-1.28)
0.97 (0.70- 1.36)

Hospital factors
Bed size
≥300
Reference
101-299
0.92 (0.49-1.72)
≤100
0.98 (0.99-2.05)
Location
Rural
Reference
Urban
1.37 (0.47-2.90)
Status
Non-teaching
Reference
Teaching
0.93 (0.43-1.15)
Type
Non-private
Reference
Private
0.56 (0.60-1.14)
a. Odds ratios are conditional or cluster-specific measures of association or intra-cluster
measures of association (Austin & Merlo, 2017).
b. Respiratory distress syndrome
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Results interpretation and hypotheses testing

This study aimed to answer two explorative research questions (research questions 1 and 2).

Question 1: What was the incidence rate of Neonatal Abstinence Syndrome in Nevada during
2016-2018, and how did it change over this time?
1a. What were the incidence rates of NAS across the two most populous counties (Washoe
vs. Clark) of Nevada?
•

The overall incidence of NAS (2016-2018) in Clark County was nearly 24% higher
than that of Washoe County. From 2016 to 2018, the incidence rates slightly declined
in Clark County, whereas Washoe County showed increasing trends.

Question 2: What were the risk factors associated with Neonatal Abstinence Syndrome?
2a. What were the neonatal risk factors associated with NAS?
•

The risk of NAS was higher among white and Medicaid insured infants. The baby’s
gender was not associated with NAS. NAS infants were more likely to be pre-term,
low birth weight, and experience respiratory problems.

2b. What were the hospital-based risk factors associated with NAS?
•

Hospital characteristics (e.g., location, status, type, and bed size) were not associated
with an increased risk of NAS.
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Additionally, this study answered two more questions with multiple testable hypotheses
related to health care utilization patterns and health care cost among NAS and non-NAS
infants.
Health care utilization patterns: For health care utilization patterns (research question # 3),
four hypotheses were tested and the decision to accept or reject each null hypothesis was
made based on the significance levels and the p-values obtained.
Question 3: What were the health care utilization patterns associated with NAS in Nevada?
3a. Were there any significant differences in hospital utilization among NAS and non-NAS
infants?
H0 3a.1: There will be no significant difference in the length of hospital stay of NAS and
non-NAS infants in Nevada.
•

An independent-samples t-test was performed to determine if there was a difference in
the length of hospital stay between NAS and non-NAS infants. The length of hospital
stay was longer among NAS infants (M=17.0, SD=14.0) than non-NAS infants
(M=2.6, SD=5.0), with a statistically significant mean difference, M = 14.4, 95% CI
[15.6,13.2], p<0.0001. The mean difference of length of stay was statistically
significant from zero and the observed p-value was below the significance level of
0.05. Therefore, null hypothesis 3a.1 was rejected.

H0 3a.2: There will be no significant difference in the proportion of hospital procedures
performed among NAS and non-NAS infants in Nevada.
•

A chi-square test was performed to determine if the proportions of intense hospital
procedures among NAS and non-NAS infants were significantly different. The
observed p-value (<0.0001) was below the significance p-value (0.05), indicating that
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the proportion of intense hospital procedures among NAS infants was statistically
different from the proportions found in non-NAS infants. Therefore, null hypothesis
#3a.2 was rejected.
H0 3a.3: There will be no significant difference in the proportions of NICU admissions
among NAS and non-NAS infants in Nevada.
•

A chi-square test was performed to determine if the proportions of NICU admissions
among NAS and non-NAS infants were significantly different. The observed p-value
(<0.0001) was below the significance p-value (0.05), indicating that the proportion of
NAS infants admitted to the NICU was statistically different from the proportions
found in non-NAS infants. Therefore, null hypothesis 3a.3 was rejected.

H0 3a.4: There will be no significant difference in the days spent in the NICU among NAS
and non-NAS infants in Nevada.
•

An independent-samples t-test was performed to determine if there was a difference in
the length of NICU stay between NAS and non-NAS infants. The NICU stay was
longer among NAS infants (M=18.2, SD =14.0) than non-NAS infants (M=10.7,
SD=13.4), with a statistically significant difference, M = 7.5, 95% CI [9.2,4.6],
p<0.0001). The mean difference of NICU stay was statistically significant from zero
and the observed p-value was below the significance level of 0.05. Therefore, null
hypothesis 3a.4 was rejected.

Health care cost: For health care cost (research question # 4), one hypothesis was tested and
the decision to accept or reject the null hypothesis was made based on the significance level
selected and the observed p-value.
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Question 4: What were the health care expenditures associated with NAS in Nevada?
4a. Were there any significant differences in the health care costs between NAS and nonNAS infants?
H0 4a.1: There will be no difference in the health care costs of NAS and non NAS infants in
Nevada.
•

An independent-samples t-test was performed to determine if there were differences
in the health care costs of treating NAS and non-NAS infants. The health care cost
was higher among NAS infants (M=$75,753 SD =$66,488) than among non-NAS
infants (M=$11,673, SD=$40,174), with a statistically significant difference, M =
$64,080, 95% CI [$70,821,$63,421], p <0.0001). The mean difference of health care
costs was statistically significant from zero and the observed p-value was below the
significance level of 0.05. Therefore, null hypothesis 4a.1 was rejected.
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Chapter 5. Discussion

In this study of infants discharged from Nevada hospitals between 2016 and 2018, we
observed a higher healthcare burden of NAS indicated by an increase in incidence, length of
stay, proportion of complicated hospital procedures, NICU admissions, and associated
hospital cost compared to uncomplicated births. The incidence rate of NAS in 2016 was 8.6
per 1,000 hospital births, which is nearly 28% greater compared to national rates (6.7 per
1,000 hospital births) (Strahan et al., 2019). This difference in the incidence can be supported
by variations in opioid prescribing rates, because Nevada had a higher opioid prescribing rate
of 80.7 prescriptions per 100 persons compared to 66.5 prescriptions per 100 persons in the
U.S. in 2016 (CDC, 2019c). Our study reports a slight decrease in NAS incidence in 20172018. This decrease could represent a true plateau in the number of cases, or it might be due
to decreased opioid prescribing rates, which dropped to 73 prescriptions per 100 persons in
Nevada in 2017 (CDC, 2019c). Reportedly, Clark County had higher opioid prescribing rates
compared to Nevada in 2016 (78 vs. 73 prescriptions per 100 persons). These rates may have
contributed to the rising NAS incidence rates in Clark County during the same period as
revealed by our study (CDC, 2019c) (Kim et al., 2019).
During the study period, a higher NAS incidence was observed among Nevada Medicaid
beneficiaries, which is consistent with previous reports (Creanga et al., 2013; Ko et al., 2016;
Patrick et al., 2012; Wang et al., 2017). In 2016-2018, nearly 7% of the total charges ($35.4
million of $524 million) related to all childbirths in Nevada were billed to Medicaid due to
NAS births alone. Substantial variations in NAS incidence by race exist, with the greatest
incidence rates among white infants (12 per 1,000 births) compared to black infants (5.4 per
1,000 births). These racial differences in NAS incidence might be due to higher prescription
drug use among white women and/or due to white pregnant women being highly motivated
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to enroll and complete drug-replacement treatments (Ailes et al., 2015; Mitchell, Severtson,
& Latimer, 2008; Saloner & Cook, 2013; Wang et al., 2017). The agents used to treat opioid
dependence (i.e., Methadone and Buprenorphine) may also lead to NAS secondary to
prenatal exposure, given their pharmacodynamic profile similar to opioids (Jones,
Kaltenbach, & Fischer, 2010; Stockman, 2012; Whelan & Remski, 2012). The disparity in
the treatment completion rates across racial groups was reported to be due to greater
unemployment, financial instability, and poor access to quality health care among the black
population (Saloner & Cook, 2013). According to a recent Nevada based study, the rate of
emergency room visits secondary to opioid, heroin, and cannabis increased among the white
population compared to other racial groups in 2016, which provides an alternative
explanation for racial disparity in terms of NAS incidence (Kim et al., 2019).

This study found higher incidence rates of NAS in urban counties as compared to rural
counties. These findings were not consistent with other nation-wide studies (Patrick et al.,
2019; Villapiano, Winkelman, Kozhimannil, Davis, & Patrick, 2017). Empirical evidence to
explain this discordant finding is lacking; however, we believe that the rural estimates in this
study are likely underestimated because residents from border rural counties may visit outof-state hospitals for delivery and may not have been admitted to Nevada hospitals. Also, the
association of urbanization and maternal substance abuse is driven by multiple complex
interrelationships based on macrolevel (availability of drugs and economic instability),
microlevel (genetic vulnerability and personality traits) and local (family) dynamics which
cannot be uncovered by a single analysis (Galea & Vlahov, 2005).

Concurrent with incidence, we observed similar trends in health care utilization patterns and
associated health care costs. NAS results in longer, and more expensive hospital stays
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compared to other uncomplicated hospital births. In 2016-2018, the average inpatient charge
and average LOS was seven times higher for NAS infants than for all Nevada infants. Our
findings of health care utilization and LOS are comparable to results from other states,
including Tennessee, Ohio, Washington, West Virginia, Florida, and Wisconsin (Atwell,
Welss, Gibson, Miller, & Corden, 2016; Bauer & Li, 2013; Creanga et al., 2012; Lind et al.,
2015; Ohio Department of Mental Health and Addiction services & Ohio Department of
Health, 2013; Patrick et al., 2012; Stabler et al., 2016; Wang et al., 2017). However, direct
comparisons of our findings with estimates of prior studies should be interpreted with caution
because of the transition of the ICD-9 to ICD-10 coding system after 2015. Unlike the ICD-9
code, the ICD-10 code (used in this study) allows for a clearer distinction between NAS
secondary to maternal substance use and one that follows therapeutic exposure to drugs
(among critically ill infants). Estimates provided by this study are expected to have a
relatively higher level of precision.
We expect our LOS and hospital charges to be slightly skewed by infants who were
presumed to be pharmacologically treated with average length of stay of more than 6 days.
Previous studies identified NAS newborns with length of stay greater than 6 days as
pharmacologically treated (Hudak & Tan, 2012; Patrick et al., 2015). In our study sample,
out of 796 NAS infants, 628 infants (78%) were presumed to receive pharmacotherapy (with
LOS > 6 days). Moreover, the extended LOS may depend on the severity of NAS symptoms,
clinical characteristics, and type (exposure) of opioid agonist used in pharmacotherapy
(Kakko, Heilig, & Sarman, 2008; Nezvalová-Henriksen, Spigset, & Nordeng, 2011).
Previous studies reported significant variations in the LOS of NAS infants subsequent to
Methadone and Buprenorphine drug replacement therapies used among their mothers
(Kokko et al., 2008). Methadone and Buprenorphine remain the standard approach to treat
opioid dependence, which act by competing with other opioids to bind with the opioid
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receptors and block them (Dixon, 2019; Kleber, 2007). Methadone is a full opioid agonist,
whereas Buprenorphine blocks opioid receptors partially, which is sufficient to reduce
craving and intensity of withdrawal symptoms (Dixon, 2019; Kleber, 2007; Whelan &
Remski, 2012). However, the risk of Buprenorphine being misused or diverted to the illegal
market also exists, which underscores the importance of understanding its pharmacokinetic,
pharmacodynamic, and safety profiles prior to use (Whelan & Remski, 2012; Yokell, Zaller,
& Rich, 2011). Compared to Methadone, Buprenorphine is well-tolerated, more efficacious,
and has better outcomes, when used as an opioid substitute among drug-dependent mothers
(Whelan & Remski, 2012). Babies born after Methadone exposure remained for an
additional 7-10 days in the hospital compared to those exposed to Buprenorphine (Jones et
al., 2010; Kakko et al., 2008). Consistent with previous reports, our study found that over
75% of the total hospital costs to treat NAS was attributed to Medicaid, substantiating that
NAS placed a significant strain on the health care system (Corr et al., 2017; Patrick et al.,
2015; Winkelman et al., 2018).

Limitations
Our study has limitations that merit discussion. First, the results of the study are not
generalizable to the entire U.S. Second, the findings are not generalizable to deliveries
occurring outside of hospitals. We suspect our county rates to be slightly underestimated
because individuals living in the border counties may seek medical care from neighboring
states. Third, a misclassification bias due to coding errors may be introduced because of the
use of hospital administrative data for reporting conditions or diseases in the form of billing
codes. Moreover, it may be subject to underreporting because administrative data typically
report fewer cases than clinical reporting (Burns & Mattick, 2007). Further, the
administrative claims data lack details to clinically assess NAS cases, in terms of severity,
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treatment outcomes, and type of drug exposure. Fourth, for the NICU days estimation, we
relied on an assumption that infants get admitted to NICU within 24 hours after birth, which
might not always be true. Fifth, only hospital charges (not the actual costs) were calculated.
In addition, the database used could only provide charges associated with hospital stay; the
information related to professional fees and readmission cost was not available. Moreover,
the cost estimates did not include expenditures to treat long-term complications due to the
inability to track patients longitudinally in the given database. Readmission rates and
associated expenditures were not calculated due to the lack of a “revisit variable” in the data
source, which would link multiple hospitalizations with the same record. Next,
discharges/admissions instead of patients were the unit of observation because identifiable
data were not available. The use of discharges may result in duplication when multiple
hospital admissions for the same patient occurred, and thereby overestimate hospitalization
rates. Lastly, due to the unavailability of a “linkage key,” linking maternal records and
neonatal records was not possible, which restricted our ability to examine maternal risk
factors. The “probabilistic matching” approach was viewed as a potential solution to link
these two data sets; however, after assessing the completeness of clinical and demographic
information common to both infant and maternal records, some important clinical variables
(e.g., delivery date, admission, discharge, and birth dates) were missing. Also, the number of
infant records were significantly higher than the maternal records, which could have
potentially produced several unlinked infants’ records. This discordance may be due to the
incomplete identification of obstetric deliveries, which are typically identified by only the
maternal outcome delivery code (Kuklina et al., 2008).
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Strengths

To our knowledge, this is the first study to examine health and financial burden of NAS in
Nevada. This report provides local level data, including county and city-wise distribution of
NAS. These findings can serve as baseline data for regional program planning and
management for reducing the burden and hospital stay associated with NAS in Nevada.

Conclusions

Given the continued rise of opioid use and prescribing rates among pregnant women, in
Nevada, the incidence rates of NAS doubled in 2016-2018 as compared to previous rates
reported in 2013. Subsequently, the financial burden and health resource utilization has also
increased with a disproportionate burden on state Medicaid programs. The baseline
information obtained from the current study provides valuable information to evaluate the
effectiveness of different state- and system-level interventions, which have been introduced
to combat this opioid epidemic.
Implications for public health practice

Findings from this study have several important implications for drug abuse treatment and
prevention programs aimed at improving the health outcomes of mother-infant dyads. A
multifaceted approach including national-, state-, and provider-level efforts will be required
to curb the NAS epidemic. Screening and education of expectant mothers, increasing access
to follow-up facilities, early intervention services for high-risk mothers and infants, and
stringent regulations for preventing opioid overprescribing, including promoting the use of
PDMPs by providers, are necessary to fight this global epidemic. More importantly,
mandated clinical reporting of Neonatal Abstinence Syndrome will be important to direct
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rapid preventive efforts without a possible time-lag associated with reporting in health
insurance claim data. Clinical reporting will also help in detailed maternal exposure history
and allow stratification of NAS according to the type of drug used for designing targeted
interventions.

Future work

This study highlights the need for additional research examining long term complications,
readmission rates and associated health care expenditures of NAS to obtain a holistic view of
the problem and establish a continuum of care. This study emphasizes the need for additional
regional (Nevada) studies to explore the multidimensional spectrum in the rural-urban
context. Prospective studies to assess rate of use/adoption (by providers) and effectiveness of
PDMPs on opioid overprescribing rates can be a crucial step in controlling this drug
epidemic and neonatal sequelae, such as NAS.

51

Appendices
Appendix A. NAS Assessment Tools
Appendix A.1. Modified Finnegan Scoring System

Modified Finnegan Scoring System
Signs and Symptoms
High pitched cry: inconsolable >15 sec or intermittently for <5 min
High pitched cry: inconsolable >15 sec AND intermittently for ≥5
min
Sleeps <1 hour after feeding
Sleeps <2 hour after feeding
Sleeps <3 hour after feeding

Score
2
3

Mild tremors: disturbed
Moderate-severe tremors: disturbed

1
2

Hyperactive Moro
Markedly Hyperactive Moro

1
2

Mild tremors: undisturbed
Moderate-severe tremors: undisturbed

1
2

Increased muscle tone

1-2

Excoriation (indicate specific area):
___________

1-2

Generalized seizure

8

Fever≥37.2 Degree Celsius

1

Frequent yawning (≥4 in an interval)

1

Sweating

1

Nasal stuffiness

1

Sneezing (≥4 in an interval)

1

Tachypnea (rate>60/min)

2

Poor feeding

2

Vomiting (or regurgitation)

2

Loose stools

2

≤ 90% of body weight

2

Excessive irritability

1-3

Total score
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3
2
1

Appendix A.2. Eat, Sleep, Console – (ESC) approach

Parameter
Eat [E]
Sleep [S]
Console [C]

Criteria
If the infant was able to breastfeed effectively or to take ≥1
oz from a bottle per feed
If child sleeps undisturbed for at least an hour
If child can be consoled within 10 minutes
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Appendix B. ICD-10-CM Diagnostic codes
Codes used for the neonatal morbidities and NAS case classification
Neonatal Diagnoses
Prematurity

ICD-10-CM codes
P0730, P0738, P0739, P0731, P0732, P0733,
P0736, P0734, P0735, P0737, P0722. P0723,
P0724, P0725, P0726

Low birth weight
Transient Tachypnea
Meconium Aspiration Syndrome

P0716, P0718
P221
P 240, P241, P242, P243, P248, P249

Respiratory Problems

P211, P219, P230, P231, P232, P233,
P235, P236, P238, P239, P289
P200, P201, P209, P210, P 220, P228,
P230, P25, P260, P270, P280, P290
P590, P591, P592, P593, P598, P599
P920, P921, P922, P923, P924, P925,
P929
P360, P361, P362, P363, P364, P365,
P369, P3619
P90
P96.1

Respiratory Distress Syndrome
Neonatal Jaundice
Feeding Difficulty
Sepsis

P234,
P229,

P928,
P368,

Seizures
Neonatal Abstinence Syndrome
(Confirmed cases)
Neonatal Abstinence Syndrome
P0414, P0417, P041A
(Suspect cases) *
*Suspect cases are newborns affected by maternal use of opiates, sedative hypnotics, and
anxiolytics.
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Appendix C. IRB protocol
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Appendix D. Classification criteria of Income Quartiles (AHRQ, 2008)
Quartile value
(2019)
1
2
3
4

Income range (in $)

Description

1-47,999
48,000-60,999
61,000-81,999
82,000+

0 to 25th percentile
26th to 50th percentile
51st to 75th percentile
76th to 100th percentile
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Appendix E. Healthcare Common Procedure Coding System
Procedure codes
6A600ZZ, 6A801ZZ, 6A650ZZ,
6A601ZZ, 6A651ZZ, 6A800ZZ

Procedure name
Phototherapy of skin

5A09357, 5A09457, 5A1935Z, 5A1955Z,
5A09557
0BH17EZ, 0BQS0ZZ, 0BH18EZ,
0B110F4, 0BJ08ZZ, 0CJS8ZZ, 0PQ00ZZ

Respiratory ventilation

06H033T, 06HP33Z, 02HW33Z,
04HY33Z, 06HY33Z, 05H833Z,
04H033Z, 02H633Z, 06H033Z, 03HP33Z,
05H533Z, 03HY33Z, 06HY32Z,
03HY32Z, 02WY33Z, 04HY32Z
02HW3DZ, 6A800ZZ
3E0G76Z, 3E0336Z, 3E0436Z, 3E0536Z,

Insertion of infusion device

0D9670Z, 0D960ZZ
0W9G3ZZ, 0W9940Z, 0W9B40Z,
0W9G00Z, 0W9930Z, 0W9900Z,
0WQ80ZZ, 0WQF0ZZ, 0B9B8ZX,
0B968ZX, 0W993ZZ, 0B9J8ZX,
0B9F8ZX
0DH67UZ, 0DH63UZ, 0DH60UZ,
0DH673Z, 0DH64UZ, 0DV44ZZ,
0DQ44ZZ
3E0F7GC, 3E0D7GC
BD11YZZ, BD15ZZZ, B01B1ZZ,
B5181ZA

Endotracheal
intubation,
repair
of
diaphragm, tracheostomy, repair of sternum

Insertion of intraluminal device
Introduction of nutritional substance into
upper GI and central vein
Drainage of stomach with drainage device,
drainage of pleural cavity and peritoneal
cavity, repair of chest and abdominal wall

Insertion of feeding device, repair of
esophagogastric junction

Introduction of therapeutic substance in
respiratory tract
Fluoroscopy of esophagus, heart

BT4JZZZ, B24BZZZ, B548ZZA,
BH48ZZZ, BT1B1ZZ, B24DYZZ

Ultrasonography

30243N1, 30233N1, 30243M1, 30233R1,
30233L1, 30233K1

Transfusion of non-autologous red blood
cells into central vein, percutaneous
approach.
Measurement of central nervous system
activity, monitoring of arterial pressure
Resection of ileum, resection of appendix

4A00X4Z, 4A133B1
0DTB0ZZ, 0DTJ0ZZ, 0D1B0Z4,
0DBN0ZZ
HZ2ZZZZ, HZ91ZZZ, HZ81ZZZ,
HZ99ZZZ

Detoxification services
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Appendix F. Dummy variable representation for NICU utilization
Levels of care
174
173
172
171

Note:

Level 4
Level 3
Level 2
Level 1
1
x
x
x
0
1
x
x
0
0
1
x
1
0
0
0
x = 0 or 1 (depends if patient directly admitted to the
highest or critical level or transferred from lower level
to the highest)
1 = admission
0 = non-admission
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Appendix G. SAS codes
SAS code for GLIMMIX Procedure

Model 1
proc glimmix data= work. import method=quad;
class ProviderID;
model NAS_Status = /dist=binomial solution cl;
random intercept /subject=ProviderID;
title “Null Multilevel logistic regression model”;
run;
Model 2
proc glimmix data=WORK.import1 method=quad;
class ProviderID GenderCode RaceCode Insurance LBW_R TT_R Seiz_R MAS_R
RespProb_R RespDist_R NJ_R FD_R Sepsis_R;
model NAS_Status = GenderCode RaceCode Insurance LBW_R premature_R TT_R
Seiz_R MAS_R RespProb_R RespDist_R NJ_R FD_R Sepsis_R / dist=binomial
solution cl;
random intercept /subject=ProviderID;
output out=out2 (keep = ID pred2) pred(ilink) = pred2;
title "Multilevel logistic regression model with patient characteristics";
run;
Model 3
proc glimmix data=WORK.import1 method=quad;
class ProviderID GenderCode RaceCode Profit_R Teaching_R Location_R BedCode
Insurance LBW_R TT_R Seiz_R MAS_R RespProb_R RespDist_R NJ_R FD_R
Sepsis_R;
model NAS_Status = GenderCode RaceCode CountyResidence Income_Quartile
Profit_R Teaching_R Location_R BedCode Insurance LBW_R premature_R TT_R
Seiz_R MAS_R RespProb_R RespDist_R NJ_R FD_R Sepsis_R /dist=binomial
solution cl;
random intercept /subject=ProviderID;
output out=out2 (keep = ID pred2) pred(ilink) = pred2;
title "Multilevel logistic regression model with patient and Hospital characteristics";
run;
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Appendix H. Correlations to assess potential collinearity among model predictors
Variable 1
Variable 2
Preterm birth
LBWa
Preterm birth
Transient tachypnea
Preterm birth
RDSb
Preterm birth
Neonatal jaundice
Preterm birth
Feeding difficulty
Preterm birth
Sepsis
Preterm birth
Seizures
LBW
RDS
LBW
Neonatal jaundice
LBW
Feeding difficulty
LBW
Sepsis
LBW
Transient tachypnea
LBW
Seizures
a. Low birth weight
b. Respiratory distress syndrome

Pearson correlation
0.674
0.144
0.339
0.297
0.161
0.172
0.009
0.244
0.215
0.111
0.122
0.089
0.007
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Appendix I. Bootstrapped chi-square outputs
Appendix I.1. Bootstrapa chi-square tests output, demographic characteristics
NAS Infants
%

All Other Hospital
Births
%

p-valueb

Demographics
Gender
Female
48.90
48.60
0.91
Male
51.00
51.10
Race
White
69.10
45.90
<0.0001
Black
10.60
13.40
Hispanic
8.80
22.50
c
API
2.30
7.00
Other
9.00
10.60
Insurance
Private
17.30
45.10
<0.0001
Medicaid
77.40
46.60
Uninsured
5.30
8.30
Income quartile
≤$47,999 (Q1)
10.50
6.63
<0.0001
$48,000-$60,999 (Q2)
51.00
50.30
$61,000-$81,999 (Q3)
36.10
39.80
$82,000 (Q4)
2.23
3.10
a. Bootstrap estimates were from 100 random samples with replacement
b. Observed p value statistically significant if <0.05
c. Asian Pacific Islander
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Appendix I.2. Bootstrapa chi-square tests output, clinical characteristics
Clinical characteristics

NAS infants
(%)
24.5
9.2
26.4
17.3

Healthy births
(%)
9.1
3.2
3.2
6.0

Prematurity
Low birth weight
Transient Tachypnea
Respiratory Distress
Syndrome
Neonatal Jaundice
44.8
14.7
Feeding Difficulty
19.0
2.4
Sepsis
9.5
2.3
a. 1000 random samples with replacement
b. Observed p-value statistically significant if <0.05
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p-valueb
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

Appendix I.3. NICU admissions and hospital procedures (Bootstrapped chi-square)
NAS
Infants
NICU utilization
Level 1
Level 2
Level 3
Level 4
Respiratory
Ventilation Support
Endotracheal intubation
repair of diaphragm, and sternum
Gastrointestinal
Insertion of feeding device, repair of
Esophagogastric junction
Infusion
Insertion of infusion device
Infusion of nutritional substance
Phototherapy of skin

All Other
Hospital Births

p-value

%

%

7.91
13.00
57.60
21.40

86.70
1.17
6.31
5.70

<0.0001
<0.0001
<0.0001
<0.0001

13.30
5.90

3.90
2.00

<0.0001
<0.0001

3.10

0.60

<0.0001

4.80
11.90
21.70

1.60
2.50
7.30

<0.0001
<0.0001
<0.0001
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Appendix J. Bootstrapped independent-samples t- test
Appendix J.1. Classical and Bootstrapped t- tests results comparison
Tests

Standard error

95% confidence intervals

Mean LOS

0.58 days

-15.50, -13.20

Mean health care cost

$2,850

-72,719, -61,523

Length of stay

0.60 days

-15.60, -13.30

Mean health care cost

$2,937

-72,939, -61,380

Classical T test

Bootstrap estimates
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Appendix J.2. Bootstrap distribution of difference in means length of stay

Distribution of DiffMeans
25

20

Percent

15

10

5

0
-16.8 -16.5 -16.2 -15.9 -15.6 -15.3 -15.0 -14.7 -14.4 -14.1 -13.8 -13.5 -13.2 -12.9 -12.6

DiffMeans

(Differences in the mean length of stay)
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Appendix J.3. Bootstrap distribution of difference in means health care cost

Distribution of DiffMeans
25

20

Percent

15

10

5

0
-77250

-74250

-71250

-68250

-65250

-62250

DiffMeans

(Differences in the mean health care cost)
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-59250

Appendix K. List of Acronyms
AAP
AA
AAFP
ASTHO
AHRQ
API
CI
CDC
CHIA
CARA
DHHS
DHCFP
ESC
HIPAA
HRSA
ICD-9-CM
ICD-10-CM
IRB
LBW
LOS
NAS
NASS
NICU
NWI
NAMSDL
OMNILC
OPR
OUD
PDMP
RDS
SPH
UNLV

American Academy of Pediatrics
Alaskan American
American Academy of Family Physicians
Association of State and Territorial Health Officials
Agency for Healthcare Research and Quality
Asian or Pacific Islander
Confidence Interval
Centers for Disease Control and Prevention
Center for Health Information Analysis
Comprehensive Addiction and Recovery Act
Department of Health and Human Services
Division of Healthcare Financing and Policy
Eat, Sleep, Console
Health Insurance Portability and Accountability Act
Health Resources and Services Administration
International Classification of Diseases, Ninth Revision, Clinical
Modification
International Classification of Diseases, Tenth Revision, Clinical
Modification
Institutional Review Board
Low birth weight
Length of stay
Neonatal Abstinence Syndrome
Neonatal Abstinence Scoring System
Neonatal Intensive Care Unit
Narcotic Withdrawal Index
National Alliance for Model State Drug Laws
Opioid Use Disorder, Maternal Outcomes, and Neonatal Abstinence
Syndrome Initiative Learning Community
Opioid prescribing rate
Opioids use disorder
Prescription Drug Monitoring Program
Respiratory Distress Syndrome
School of Public Health
University of Nevada, Las Vegas
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Appendix L. List of Definitions

Average length of stay
Binary variable
Bootstrap analysis
Collinearity
Diagnostic code
In-utero exposure
Kangaroo care
Meconium aspiration
syndrome
Medicaid discharge
NAS hospitalization
rate
NICU
Opioids

Preterm birth
Procedure code
Respiratory distress
syndrome
Revenue code
Rooming-in
Transient tachypnoea

The average number of days in an in-patient setting
Variable with two responses
This allows estimation of the sampling distribution of any
statistic using random sampling.
Correlation between two independent variables
A tool to group and identify diseases and conditions in health
care data
Exposure to licit or illicit substances in the womb
Skin to skin contact between parent (typically mother) and baby
The baby has passed meconium (stool) into the amniotic fluid
during labor or delivery
A person who has Medicaid as a payer source
The number of in-patient NAS hospitalizations divided by the
number of live births to Nevada residents, giving birth in
Nevada. The rate is presented in units per 1,000 hospital births.
Specialized care unit for critically- ill or premature babies
Class of drugs that include the illegal drug heroin, synthetic
opioids such as fentanyl and pain relievers available legally by
prescription, such as Oxycontin, morphine, hydrocodone etc.
Babies born prior to 37 completed weeks of gestation
A tool used to identify specific surgical, medical, or diagnostic
procedures
Breathing problem which occurs when the lungs of the baby are
not fully developed
Revenue codes are 3-digit numbers that are used to describe the
setting in which a patient receives a specific type of treatment
Practice in which a baby’s crib is kept by the side of the
mother’s bed
Rapid breathing rate
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